Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the sale, the insider now directly owns 209,661 shares in the company, valued at $7,193,468.91. This trade represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Hims & Hers Health Stock Down 9.3 %
Shares of HIMS opened at $31.46 on Wednesday. The stock has a fifty day simple moving average of $38.72 and a two-hundred day simple moving average of $28.49. The company has a market capitalization of $6.99 billion, a PE ratio of 71.49 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on HIMS shares. Citigroup reissued a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $37.31.
Read Our Latest Research Report on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Market Cap Calculator: How to Calculate Market Cap
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Following Congress Stock Trades
- 3 Must-Own Stocks to Build Wealth This Decade
- Health Care Stocks Explained: Why You Might Want to Invest
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.